Patents by Inventor Lijie Zhan

Lijie Zhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20110257175
    Abstract: The invention provides new compounds and compositions thereof. The invention also provides methods for treating ophthalmic diseases, disorders and conditions.
    Type: Application
    Filed: April 8, 2011
    Publication date: October 20, 2011
    Inventors: Stëphane Raeppel, Lijie Zhan, Stephen William Claridge, Franck Raeppel, Frëdëric Gaudette, Arkadii Vaisburg
  • Publication number: 20110098293
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Application
    Filed: February 27, 2009
    Publication date: April 28, 2011
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Publication number: 20110077240
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Application
    Filed: December 9, 2010
    Publication date: March 31, 2011
    Inventors: Michael Mannion, Stéphane Raeppel, Stephen William Claridge, Frédéric Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Publication number: 20100249145
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: March 25, 2010
    Publication date: September 30, 2010
    Inventors: Oscar Mario Saavedra, Stephen William Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Z. Zhou, Ljubomir Isakovic
  • Patent number: 7790729
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: September 7, 2010
    Assignee: Methylgene Inc.
    Inventors: Oscar Mario Saavedra, Stephen William Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Z. Zhou, Ljubomir Isakovic
  • Publication number: 20100216766
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: May 6, 2010
    Publication date: August 26, 2010
    Inventors: Arkadii Vaisburg, Stephen William Clarige, Franck Raepael, Oscar Mario Saavedra, Naomy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Liewellyn
  • Patent number: 7772247
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: August 10, 2010
    Assignee: Methylgene Inc.
    Inventors: Arkadii Vaisburg, Stephen William Claridge, Franck Raeppel, Oscar Mario Saavedra, Naomy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Llewellyn
  • Publication number: 20090286984
    Abstract: This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Application
    Filed: August 29, 2008
    Publication date: November 19, 2009
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg, Miguel Nantel
  • Publication number: 20090264440
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: August 29, 2008
    Publication date: October 22, 2009
    Inventors: Stephen William Claridge, Ljubomir Isakovic, Michael Mannion, Stephane Raeppel, Oscar Mario Saavedra, Frederic Gaudette, Lijie Zhan, Nancy Z. Zhou, Franck Raeppel, Robert Deziel, Arkadii Vaisburg, Tetsuyuki Uno
  • Publication number: 20080064718
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: March 22, 2007
    Publication date: March 13, 2008
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Frederic Gaudette, Ljubomir Isakovic, Marie Granger, Jubrail Rahil, Michael Mannion, Robert Deziel
  • Publication number: 20080004273
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: May 30, 2007
    Publication date: January 3, 2008
    Inventors: Stephane Raeppel, Stephen Claridge, Oscar Saavedra, Arkadii Vaisburg, Robert Deziel, Lijie Zhan, Michael Mannion, Frederic Gaudette, Nancy Zhou, Ljubomir Isakovic
  • Publication number: 20070004675
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: May 19, 2006
    Publication date: January 4, 2007
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Zhou, Frederic Gaudette, Ljubomir Isakovic, Amal Wahhab, Marie-Claude Granger, Naomy Bernstein
  • Publication number: 20060287343
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: May 19, 2006
    Publication date: December 21, 2006
    Inventors: Oscar Saavedra, Stephen Claridge, Lijie Zhan, Franck Raeppel, Arkadii Vaisburg, Stephane Raeppel, Robert Deziel, Michael Mannion, Nancy Zhou, Ljubomir Isakovic
  • Publication number: 20060074056
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Application
    Filed: July 28, 2005
    Publication date: April 6, 2006
    Applicant: MethylGene, Inc.
    Inventors: Arkadii Vaisburg, Stephen Claridge, Franck Raeppel, Oscar Saavedra, Naomy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Llewellyn